Predict your next investment

Evrys Bio company logo
HEALTHCARE | Drug Development
evrys.com

See what CB Insights has to offer

Founded Year

2012

Stage

Grant | Alive

Total Raised

$37.87M

Last Raised

$34.3M | 17 days ago

Revenue

$0000 

About Evrys Bio

Evrys Bio aims to develop antivirals that are safe, address the problem of acquired drug resistance, and provide unique broad-spectrum treatment options. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the cell’s intrinsic immunity to defend against infection.

Evrys Bio Headquarter Location

3805 Old Easton Road

Doylestown, Pennsylvania, 18902,

United States

609-874-9013

Latest Evrys Bio News

08:34 ET International Scientific Advisors Announces Evrys Bio Awarded $34 Million from DoD

Nov 23, 2021

Partnership and Funding Intended to Accelerate Development of a Single Drug Simultaneously Effective Against Multiple Lethal Viruses News provided by Share this article Share this article BEAVERTON, Ore., Nov. 23, 2021 /PRNewswire/ --  International Scientific Advisors  (ISA), a tech-enabled marketplace that activates military veteran expertise to advance biomedical tech, has announced that client Evrys Bio  has received a $34 million award from the United States Department of Defense (DoD) to advance treatment for alphavirus, arenavirus, and filovirus infections. The Defense Threat Reduction Agency's Chem Bio Technologies, Vaccines, and Therapeutics Division executed the $34.3 million contract with Evrys to develop a drug simultaneously effective against multiple high-risk viral agents. The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses, and filoviruses. The Defense Threat Reduction Agency (DTRA), an agency within the DoD, is the official Combat Support Agency for countering weapons of mass destruction (chemical, biological, radiological, nuclear, and high explosives). Evrys Bio's broad-spectrum antiviral technology is based on the discovery that certain human proteins, called sirtuins, normally defend the human (host) cell from being invaded by pathogens. The novel drug will target the human SIRT-2 protein. Dr. Eric Hanson MD, MPH, CEO of ISA, shared how the company supports clients in securing funding, "For organizations who seek to quickly and efficiently address global challenges in medical technology, biotech, healthcare, defense, and other key sectors, International Scientific Advisors offers high-specialized and well-trained Veteran biomedical talent. Our top-tier Scientific Advisors, combined with access to resources, data, and tools, help drive innovation, capture non-dilutive funding, and take new technologies to market. Our partnership with Evrys is a perfect example of the powerful impact ISA can have on our clients' success." Founded on breakthrough discoveries made at Princeton University, Evrys Bio focuses on developing antivirals that engage a cell's intrinsic immunity to defend against infection. Lillian Chiang, CEO of Evrys Bio, stated, "At Evrys Bio, we are developing broad-spectrum antivirals that engage the patient's own immunity to defend against viral infection. Our pipeline has therapeutic utility in multiple areas of significant unmet medical need. Dr. Hanson and the ISA team helped Evrys obtain non-dilutive funding for application of our technology to medical countermeasures. Our five-year partnership with ISA has yielded many unique funding opportunities and opened doors to business relationships with Department of Defense (DoD) researchers and DoD components personnel, such as the Defense Threat Reduction Agency (DTRA), ultimately helping us to secure this significant funding." To access Evrys Bio's press release, click here . To learn more about International Scientific Advisors, please visit joinisa.io . About International Scientific Advisors International Scientific Advisors, Inc., a Techstars portfolio company, is a Delaware Corporation headquartered in Beaverton, Oregon, that leverages technology, training, and connectivity to power a marketplace for top-tier biomedical talent, providing access to military Veteran experts, resources, and support to accelerate the commercialization of biomedical tech. Learn more at joinisa.io Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Evrys Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Evrys Bio is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Evrys Bio Patents

Evrys Bio has filed 2 patents.

The 3 most popular patent topics include:

  • Amines
  • Antivirals
  • Betaherpesvirinae
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/21/2020

Viral diseases, Stimulants, Betaherpesvirinae, Amines, Designer drugs

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/21/2020

00/00/0000

Grant Date

00/00/0000

Title

Subscribe to see more

Related Topics

Viral diseases, Stimulants, Betaherpesvirinae, Amines, Designer drugs

Subscribe to see more

Status

Application

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.